Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;33(4):751-68.
doi: 10.2190/K0JG-EXG1-FB12-0ANF.

Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals

Affiliations

Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals

Alexander C Tsai. Int J Health Serv. 2003.

Abstract

In 1992, researchers from the University of California, Los Angeles, published a study on the scientific merit and validity of pharmaceutical advertisements in medical journals. Their results led them to conclude, provocatively, that many pharmaceutical advertisements contained deficiencies in areas in which the U.S. Food and Drug Administration had established explicit standards of quality. This article provides a detailed account of third-party reactions to the study following its publication in the Annals of Internal Medicine, as well as the implications for those involved, including the authors, editors, and publisher. The increasingly diverging interests between medical journal editors and publishers are also discussed and highlighted by two recent cases of editors' departures from prominent general-interest medical journals.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann. Intern. Med. 1992;116:912–919. - PubMed
    1. Kessler DA. Addressing the problem of misleading advertising. Ann. Intern. Med. 1992;116:950–951. - PubMed
    1. Kunin CM. Blunder drug for pneumonia. N. Engl. J. Med. 1977;297:113–114. - PubMed
    1. Tannock IF. Responsibility in advertising: an oncologist’s view. N. Engl. J. Med. 1979;301:1004. - PubMed
    1. Potter HP., Jr. Costs of drug advertising. N. Engl. J. Med. 1988;319:798. - PubMed

Publication types

LinkOut - more resources